
US Merck Snaps up Prometheus Biosciences for $10.8 Billion
Shares of Prometheus Biosciences soared on news that US drugs major Merck will acquire the company in an all-cash deal valued at roughly $200 per share, or $10.8 billion.
Shares of Prometheus Biosciences soared on news that US drugs major Merck will acquire the company in an all-cash deal valued at roughly $200 per share, or $10.8 billion.
Ahead of a change in leadership at the top after the upcoming annual general meeting, in interviews with news agencies Bayer is dropping hints in dribbles about future plans for its healthcare business.
Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.